September 6, 2011

August 31, 2011

July 11, 2011

Epizyme and Collaborators Publish Paper in Cancer Cell Supporting Use of DOT1L Histone Methyltransferase Inhibitors as Personalized Therapeutics for Genetically-Defined MLL-rearranged Leukemia Patients

June 23, 2011

The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients

April 27, 2011

Epizyme Named # 1 Worldwide in The Scientist's "Best Places to Work - Industry 2011" Survey

March 10, 2011

Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme

January 10, 2011

Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics 

January 6, 2011

Multiple Myeloma Research Foundation (MMRF) Invests $3 Million In Development of Next-Generation Treatments

November 23, 2010

Epizyme Announces Oral Presentations at 52nd ASH Annual Meeting and Exposition in Orlando, Florida

November 15, 2010

Epizyme Publication Identifies Novel Opportunity for Treatment of Genetically-Defined Human B-cell Lymphomas -- Research in PNAS Reveals Unique Role of EZH2 Enzyme in Cancer, Facilitating Development of Selective Small Molecule Therapeutics

November 3, 2010

Epizyme Awarded $733,000 Grant under Qualified Therapeutic Discovery Project Program -- Funds to Support Development of Epigenetic Enzyme Inhibitors to Treat Cancer

July 16, 2010

Epizyme Scientists Detail Epigenetic Approaches to Cancer Therapy in Drug Discovery Today: Therapeutic Strategies and Current Opinion in Chemical Biology

May 14, 2010

Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery

March 24, 2010

Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO

December 8, 2009

Epizyme Closes $40M Series B Financing NEA Joins Syndicate;
NEA's David Mott Joins Board

October 20, 2009

Epizyme Appoints Hoyoung Huh, MD, Ph.D., Chairman of the Board of Directors

October 7, 2009

Epizyme Closes $32 Million Series B Financing, Led By New Investor Bay City Capital

© 2012 Epizyme, Inc. - All Rights Reserved  |  Home  |  Site Map  |  Legal  |  Contact  |  Careers